Summary of COVID-19 goflikicept studies

1. Samsonov et al., An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)

248 patient goflikicept late treatment RCT: 135% higher mortality (p=0.07) and no change in improvement (p=1).
RCT 248 hospitalized patients showing higher mortality (p=0.07) with goflikicept (RPH-104).
Jan 2022, NCT04380519, https://clinicaltrials.gov/study/NCT04380519, https://c19p.org/samsonov